Application of lentinan to prevention or treatment of cardiovascular and cerebrovascular diseases

Abstract

The invention discloses application of lentinan to preparation of a medicament for preventing or treating cardiovascular and cerebrovascular diseases of a subject. Particularly, the lentinan preventsor treats the cardiovascular and cerebrovascular diseases by preventing or treating hypertension, can obviously reduce a systolic pressure and can obviously improve aortic wall thickening, aorta fibrosis area increase, an elevated aorta oxidative stress level and the like caused by hypertension. The invention provides a novel drug choice for the cardiovascular and cerebrovascular diseases and solves problems of no medicament for carrying out effective prevention and treatment on hypertension and complication thereof and adverse reaction of clinical medicine treatment conventionally.

Description

technical field

[0001] The invention relates to the field of medicine, in particular to the use of lentinan in the prevention or treatment of cardiovascular and cerebrovascular diseases, in particular to the use of lentinan in the preparation of medicines for the prevention or treatment of hypertension. Background technique

[0002] The prevalence of cardiovascular disease (CVD) in China continues to rise, and the mortality rate ranks first among various diseases, and it has become one of the most important public health problems today. As a major risk factor for CVD, hypertension affects 30% of adults and 70% of older adults. Among the 290 million CVD patients, 87% are hypertensive patients. Hypertension can lead to stroke, coronary atherosclerotic heart disease, heart failure and cardiac arrhythmia, significantly increase the mortality and disability, and seriously affect the prognosis of patients with cardiovascular disease. Therefore, the molecular mechanism and preven...

Examples

Embodiment 1

[0038] Establish an Ang II-induced hypertension model in mice: take 6-8 week-old SPF grade male C57BL / 6 mice, disinfect the operation area with 75% alcohol after anesthesia, subcutaneously bury and infuse normal saline or 490ng / kg / min Ang II in the back of the mouse The micro sustained-release pump of II was used for 2 weeks, during which the blood pressure was continuously monitored to confirm that the mouse model of hypertension was successfully established.

technical field

[0001] The invention relates to the field of medicine, in particular to the use of lentinan in the prevention or treatment of cardiovascular and cerebrovascular diseases, in particular to the use of lentinan in the preparation of medicines for the prevention or treatment of hypertension. Background technique

[0002] The prevalence of cardiovascular disease (CVD) in China continues to rise, and the mortality rate ranks first among various diseases, and it has become one of the most important public health problems today. As a major risk factor for CVD, hypertension affects 30% of adults and 70% of older adults. Among the 290 million CVD patients, 87% are hypertensive patients. Hypertension can lead to stroke, coronary atherosclerotic heart disease, heart failure and cardiac arrhythmia, significantly increase the mortality and disability, and seriously affect the prognosis of patients with cardiovascular disease. Therefore, the molecular mechanism and preven...

Examples

Embodiment 1

[0038] Establish an Ang II-induced hypertension model in mice: take 6-8 week-old SPF grade male C57BL / 6 mice, disinfect the operation area with 75% alcohol after anesthesia, subcutaneously bury and infuse normal saline or 490ng / kg / min Ang II in the back of the mouse The micro sustained-release pump of II was used for 2 weeks, during which the blood pressure was continuously monitored to confirm that the mouse model of hypertension was successfully established.

Images